patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_133670 | REC_0011201 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 6 | 62 | female | 1 | 62 | 7.1 | 2 | pembrolizumab 200 mg q3w | 28 | false | MSS | 2026-03-15T05:35:59.662460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604647 | REC_0011202 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 15.6 | 77 | female | 2 | 17 | 3.1 | 4 | pembrolizumab 200 mg q3w | 9 | true | MSI-H | 2026-03-15T05:35:59.662695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769406 | REC_0011203 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 21 | 5.4 | 69 | female | 0 | 15 | 5 | 0 | entrectinib 600 mg daily | 52.9 | false | MSS | 2026-03-15T05:35:59.662923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287501 | REC_0011204 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 18 | 10.4 | 81 | female | 2 | 18 | 7.7 | 0 | osimertinib 80 mg daily | 57.1 | true | MSS | 2026-03-15T05:35:59.663159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107612 | REC_0011205 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 16.3 | 60 | male | 1 | 6 | 5.9 | 5 | entrectinib 600 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:59.663395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513529 | REC_0011206 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 7.8 | 62 | female | 0 | 48 | 7.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.2 | false | MSS | 2026-03-15T05:35:59.663627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187843 | REC_0011207 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 9.5 | 79 | female | 0 | 11 | 4.5 | 1 | osimertinib 80 mg daily | 19.2 | true | MSS | 2026-03-15T05:35:59.663908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305059 | REC_0011208 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 33 | 7.5 | 58 | male | 0 | 7 | 6.1 | 1 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:59.664181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790821 | REC_0011209 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 16.9 | 67 | female | 1 | 14 | 6 | 1 | sotorasib 960 mg daily | 17.1 | false | MSI-H | 2026-03-15T05:35:59.664425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602959 | REC_0011210 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 9.2 | 83 | male | 2 | 3 | 5 | 6 | sotorasib 960 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.664667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938724 | REC_0011211 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.1 | 66 | female | 0 | 9 | 5 | 7 | alectinib 600 mg BID | 13.9 | true | MSI-H | 2026-03-15T05:35:59.664899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757412 | REC_0011212 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 2.3 | 47 | male | 0 | 61 | 5.5 | 5 | pembrolizumab 200 mg q3w | 7.9 | false | MSS | 2026-03-15T05:35:59.665131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_231367 | REC_0011213 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.7 | 75 | male | 2 | 8 | 7.2 | 5 | sotorasib 960 mg daily | 7.8 | true | MSS | 2026-03-15T05:35:59.665369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687062 | REC_0011214 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 5.6 | 69 | female | 0 | 18 | 5.2 | 3 | alectinib 600 mg BID | 16.5 | false | MSS | 2026-03-15T05:35:59.665596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880809 | REC_0011215 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 11.1 | 53 | female | 0 | 9 | 4.9 | 1 | alectinib 600 mg BID | 11 | false | MSS | 2026-03-15T05:35:59.665830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429297 | REC_0011216 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 4 | 60 | male | 0 | 11 | 5.9 | 2 | pembrolizumab 200 mg q3w | 27 | false | MSS | 2026-03-15T05:35:59.666066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565199 | REC_0011217 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.7 | 67 | female | 0 | 4 | 4.9 | 5 | alectinib 600 mg BID | 16.5 | false | MSS | 2026-03-15T05:35:59.666302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446505 | REC_0011218 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 6 | 64 | female | 0 | 11 | 5.5 | 2 | alectinib 600 mg BID | 32.4 | true | MSS | 2026-03-15T05:35:59.666534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519167 | REC_0011219 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 18.8 | 78 | female | 1 | 5 | 5.5 | 4 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:59.666769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963200 | REC_0011220 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 19.6 | 73 | male | 2 | 6 | 5.6 | 6 | entrectinib 600 mg daily | 8.9 | true | MSI-H | 2026-03-15T05:35:59.667048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715828 | REC_0011221 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.3 | 80 | male | 1 | 13 | 6.1 | 7 | alectinib 600 mg BID | 14.6 | true | MSS | 2026-03-15T05:35:59.667291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366017 | REC_0011222 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 15.4 | 60 | female | 1 | 10 | 3.9 | 6 | osimertinib 80 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:59.667531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871774 | REC_0011223 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 8.2 | 72 | male | 1 | 15 | 4.9 | 2 | entrectinib 600 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:59.667768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887427 | REC_0011224 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 12.7 | 82 | female | 1 | 9 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 18.3 | true | MSS | 2026-03-15T05:35:59.668001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470748 | REC_0011225 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 10 | 71 | female | 2 | 6 | 5.5 | 2 | osimertinib 80 mg daily | 19.6 | false | MSI-H | 2026-03-15T05:35:59.668305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679795 | REC_0011226 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 34 | 6.5 | 75 | male | 3 | 22 | 2.6 | 2 | pembrolizumab 200 mg q3w | 22.7 | false | MSS | 2026-03-15T05:35:59.668557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954048 | REC_0011227 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.9 | 56 | male | 1 | 10 | 3.4 | 8 | entrectinib 600 mg daily | 8.7 | true | MSI-H | 2026-03-15T05:35:59.668797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572258 | REC_0011228 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.3 | 63 | female | 0 | 12 | 4.5 | 5 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:35:59.669057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842166 | REC_0011229 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 35 | 12.2 | 68 | female | 0 | 9 | 8.5 | 5 | alectinib 600 mg BID | 7 | false | MSS | 2026-03-15T05:35:59.669297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236384 | REC_0011230 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 3.4 | 70 | female | 1 | 20 | 5.3 | 5 | alectinib 600 mg BID | 11.5 | true | MSS | 2026-03-15T05:35:59.669523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390684 | REC_0011231 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 12.6 | 68 | female | 0 | 13 | 6.2 | 1 | alectinib 600 mg BID | 17 | true | MSI-H | 2026-03-15T05:35:59.669756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157499 | REC_0011232 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.3 | 50 | female | 0 | 64 | 6.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.7 | false | MSS | 2026-03-15T05:35:59.669985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530895 | REC_0011233 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 8.2 | 55 | female | 1 | 11 | 5.3 | 4 | entrectinib 600 mg daily | 6 | false | MSS | 2026-03-15T05:35:59.670276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390057 | REC_0011234 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.9 | 69 | female | 0 | 17 | 3.7 | 4 | alectinib 600 mg BID | 6.3 | false | MSS | 2026-03-15T05:35:59.670506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199808 | REC_0011235 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.9 | 73 | female | 1 | 15 | 6.1 | 4 | pembrolizumab 200 mg q3w | 8.5 | true | MSS | 2026-03-15T05:35:59.670734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671200 | REC_0011236 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 7.4 | 77 | female | 1 | 18 | 4.9 | 2 | alectinib 600 mg BID | 19 | false | MSS | 2026-03-15T05:35:59.670961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204927 | REC_0011237 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.3 | 66 | female | 0 | 1 | 6 | 6 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:59.671192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824847 | REC_0011238 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 12.1 | 70 | female | 0 | 6 | 7.5 | 5 | osimertinib 80 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:35:59.671421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932553 | REC_0011239 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.6 | 71 | female | 0 | 43 | 6.3 | 6 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:35:59.671658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420906 | REC_0011240 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 13.5 | 69 | female | 1 | 15 | 6.8 | 4 | alectinib 600 mg BID | 11.3 | true | MSI-H | 2026-03-15T05:35:59.671902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384555 | REC_0011241 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.7 | 84 | female | 1 | 76 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.9 | false | MSS | 2026-03-15T05:35:59.672286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777553 | REC_0011242 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.3 | 66 | female | 0 | 20 | 3.6 | 6 | sotorasib 960 mg daily | 15 | false | MSS | 2026-03-15T05:35:59.672554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584311 | REC_0011243 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 10.2 | 71 | female | 2 | 19 | 3.8 | 5 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:35:59.672823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745030 | REC_0011244 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.7 | 72 | female | 1 | 21 | 7.3 | 8 | osimertinib 80 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:59.673074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761474 | REC_0011245 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.1 | 68 | female | 0 | 15 | 6.9 | 7 | osimertinib 80 mg daily | 7.2 | true | MSS | 2026-03-15T05:35:59.673324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282618 | REC_0011246 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.3 | 64 | female | 1 | 44 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 5.5 | true | MSS | 2026-03-15T05:35:59.673742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245332 | REC_0011247 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.1 | 60 | female | 0 | 19 | 5.1 | 2 | pembrolizumab 200 mg q3w | 9.2 | false | MSS | 2026-03-15T05:35:59.674014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167524 | REC_0011248 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.5 | 75 | male | 2 | 36 | 4.2 | 4 | pembrolizumab 200 mg q3w | 13.4 | false | MSS | 2026-03-15T05:35:59.674257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584784 | REC_0011249 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 17 | 61 | female | 0 | 11 | 6.3 | 5 | osimertinib 80 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:59.674502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644232 | REC_0011250 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.7 | 71 | female | 0 | 9 | 4.6 | 6 | osimertinib 80 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:59.674744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417970 | REC_0011251 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 11.4 | 73 | female | 1 | 31 | 4.8 | 2 | sotorasib 960 mg daily | 27.1 | false | MSS | 2026-03-15T05:35:59.674991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747782 | REC_0011252 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 14.1 | 57 | female | 0 | 9 | 5.5 | 2 | osimertinib 80 mg daily | 26.9 | true | MSI-H | 2026-03-15T05:35:59.675237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876547 | REC_0011253 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.2 | 68 | female | 1 | 23 | 5.8 | 3 | osimertinib 80 mg daily | 4.5 | true | MSS | 2026-03-15T05:35:59.675479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316346 | REC_0011254 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 4 | 66 | female | 0 | 33 | 4.8 | 0 | osimertinib 80 mg daily | 41.3 | true | MSS | 2026-03-15T05:35:59.675715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984642 | REC_0011255 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 28 | 9.9 | 68 | female | 1 | 18 | 7.4 | 0 | alectinib 600 mg BID | 21.3 | true | MSS | 2026-03-15T05:35:59.675963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483141 | REC_0011256 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 36 | 15.5 | 81 | female | 2 | 10 | 6 | 6 | entrectinib 600 mg daily | 6.4 | true | MSI-H | 2026-03-15T05:35:59.676534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978190 | REC_0011257 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 10.9 | 75 | female | 1 | 17 | 6.4 | 6 | osimertinib 80 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:59.676841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622815 | REC_0011258 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 13.1 | 66 | male | 1 | 26 | 4.9 | 5 | sotorasib 960 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:35:59.677110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656226 | REC_0011259 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 14.6 | 64 | female | 0 | 1 | 4.2 | 1 | sotorasib 960 mg daily | 16.5 | false | MSI-H | 2026-03-15T05:35:59.677553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104738 | REC_0011260 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 11.6 | 57 | female | 1 | 21 | 5.8 | 2 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.677822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111265 | REC_0011261 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 21 | 81 | female | 2 | 11 | 4.4 | 2 | osimertinib 80 mg daily | 14.6 | false | MSS | 2026-03-15T05:35:59.678064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462204 | REC_0011262 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 9.1 | 70 | female | 1 | 21 | 4.6 | 3 | alectinib 600 mg BID | 11.2 | false | MSS | 2026-03-15T05:35:59.678305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585324 | REC_0011263 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 14.8 | 68 | female | 0 | 6 | 5.1 | 2 | alectinib 600 mg BID | 15.8 | true | MSS | 2026-03-15T05:35:59.678556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223848 | REC_0011264 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 12 | 67 | female | 0 | 9 | 5.6 | 1 | osimertinib 80 mg daily | 29.4 | false | MSS | 2026-03-15T05:35:59.678822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569351 | REC_0011265 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 14 | 14.6 | 58 | male | 1 | 27 | 5.5 | 1 | osimertinib 80 mg daily | 16.6 | true | MSI-H | 2026-03-15T05:35:59.679112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902512 | REC_0011266 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.6 | 70 | female | 1 | 14 | 3.6 | 4 | alectinib 600 mg BID | 14.7 | false | MSS | 2026-03-15T05:35:59.679392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583108 | REC_0011267 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 19 | 9.5 | 74 | female | 1 | 9 | 3.2 | 0 | osimertinib 80 mg daily | 27 | false | MSS | 2026-03-15T05:35:59.679648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434418 | REC_0011268 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 28 | 3.8 | 67 | female | 1 | 9 | 5.3 | 0 | sotorasib 960 mg daily | 24.6 | false | MSS | 2026-03-15T05:35:59.680031+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175839 | REC_0011269 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 8.1 | 57 | male | 2 | 13 | 4.9 | 1 | osimertinib 80 mg daily | 24.9 | true | MSS | 2026-03-15T05:35:59.680529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679469 | REC_0011270 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.6 | 65 | male | 1 | 7 | 6 | 6 | entrectinib 600 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:59.680825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600956 | REC_0011271 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.5 | 69 | female | 0 | 53 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.2 | false | MSS | 2026-03-15T05:35:59.681085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186373 | REC_0011272 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 10.4 | 62 | male | 1 | 18 | 5.4 | 6 | sotorasib 960 mg daily | 8.3 | true | MSI-H | 2026-03-15T05:35:59.681456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925307 | REC_0011273 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 16.9 | 75 | female | 1 | 17 | 4.8 | 0 | osimertinib 80 mg daily | 31.3 | false | MSS | 2026-03-15T05:35:59.681716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721509 | REC_0011274 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 9.2 | 75 | female | 3 | 17 | 6.4 | 5 | pembrolizumab 200 mg q3w | 5.3 | true | MSS | 2026-03-15T05:35:59.681963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194784 | REC_0011275 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 7.3 | 69 | female | 1 | 13 | 7.4 | 7 | osimertinib 80 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:59.682221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697408 | REC_0011276 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 3.8 | 68 | female | 1 | 55 | 6.1 | 1 | pembrolizumab 200 mg q3w | 24.4 | false | MSS | 2026-03-15T05:35:59.682466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480810 | REC_0011277 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 20.6 | 77 | female | 2 | 3 | 6.1 | 0 | osimertinib 80 mg daily | 20.2 | false | MSI-H | 2026-03-15T05:35:59.682719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397402 | REC_0011278 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 16.4 | 65 | male | 1 | 8 | 7.2 | 4 | entrectinib 600 mg daily | 9.7 | true | MSS | 2026-03-15T05:35:59.682972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109678 | REC_0011279 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 14.1 | 72 | female | 3 | 3 | 5.8 | 2 | alectinib 600 mg BID | 11.5 | false | MSS | 2026-03-15T05:35:59.683214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986129 | REC_0011280 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 18.4 | 63 | female | 0 | 19 | 6 | 7 | sotorasib 960 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:59.683462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266387 | REC_0011281 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 7.4 | 74 | male | 1 | 10 | 6.4 | 7 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:59.683717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198531 | REC_0011282 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 6.4 | 69 | female | 0 | 9 | 4.2 | 4 | sotorasib 960 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:59.683974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657856 | REC_0011283 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 13 | 66 | female | 1 | 15 | 4.8 | 6 | osimertinib 80 mg daily | 6.2 | false | MSS | 2026-03-15T05:35:59.684297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801373 | REC_0011284 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 14 | 63 | female | 0 | 12 | 5.3 | 4 | sotorasib 960 mg daily | 8.1 | true | MSI-H | 2026-03-15T05:35:59.684557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571630 | REC_0011285 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 17.3 | 71 | male | 2 | 15 | 5.7 | 8 | sotorasib 960 mg daily | 15.6 | true | MSI-H | 2026-03-15T05:35:59.684927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662617 | REC_0011286 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 6.3 | 68 | male | 0 | 21 | 5 | 1 | alectinib 600 mg BID | 10.8 | false | MSS | 2026-03-15T05:35:59.685179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982507 | REC_0011287 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 11.5 | 73 | female | 3 | 20 | 6 | 2 | osimertinib 80 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:35:59.685415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551435 | REC_0011288 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.5 | 57 | female | 0 | 13 | 2.5 | 3 | alectinib 600 mg BID | 11.6 | true | MSS | 2026-03-15T05:35:59.685657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327537 | REC_0011289 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.2 | 66 | female | 0 | 71 | 4.9 | 4 | pembrolizumab 200 mg q3w | 6.8 | false | MSS | 2026-03-15T05:35:59.685889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302998 | REC_0011290 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.8 | 69 | female | 0 | 9 | 6.7 | 5 | pembrolizumab 200 mg q3w | 8.4 | true | MSS | 2026-03-15T05:35:59.686126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902674 | REC_0011291 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 18.2 | 73 | female | 2 | 10 | 6.7 | 6 | osimertinib 80 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:59.686359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313774 | REC_0011292 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 8.2 | 72 | female | 1 | 21 | 5.4 | 2 | osimertinib 80 mg daily | 23.8 | true | MSS | 2026-03-15T05:35:59.686587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111980 | REC_0011293 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.3 | 62 | male | 0 | 41 | 4.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:35:59.686825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289079 | REC_0011294 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 10.8 | 68 | female | 0 | 24 | 3.8 | 5 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.687059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582000 | REC_0011295 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 12.2 | 61 | male | 0 | 13 | 5.7 | 2 | entrectinib 600 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:35:59.687293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755203 | REC_0011296 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.2 | 66 | female | 1 | 20 | 5 | 3 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:59.687525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816359 | REC_0011297 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 14.5 | 56 | male | 0 | 26 | 5.2 | 2 | sotorasib 960 mg daily | 24.4 | false | MSS | 2026-03-15T05:35:59.687760+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918797 | REC_0011298 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 13.2 | 73 | female | 2 | 8 | 5.3 | 4 | pembrolizumab 200 mg q3w | 9.8 | true | MSI-H | 2026-03-15T05:35:59.688038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169807 | REC_0011299 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.4 | 75 | male | 1 | 14 | 7.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:59.688326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217714 | REC_0011300 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.9 | 66 | female | 1 | 4 | 6.8 | 6 | sotorasib 960 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:59.688564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.